RU2014132706A - Нуклеиновые кислоты, специфически связывающие cgrp - Google Patents

Нуклеиновые кислоты, специфически связывающие cgrp Download PDF

Info

Publication number
RU2014132706A
RU2014132706A RU2014132706A RU2014132706A RU2014132706A RU 2014132706 A RU2014132706 A RU 2014132706A RU 2014132706 A RU2014132706 A RU 2014132706A RU 2014132706 A RU2014132706 A RU 2014132706A RU 2014132706 A RU2014132706 A RU 2014132706A
Authority
RU
Russia
Prior art keywords
nucleic acid
seq
acid molecule
molecule according
cgrp
Prior art date
Application number
RU2014132706A
Other languages
English (en)
Russian (ru)
Inventor
Зимоне ШУЛЬЦХЕН
Вернер ПУРШКЕ
Флориан Ярош
Кай ХЕЛИГ
Кристиан Мааш
Свен Клуссманн
Original Assignee
Ноксон Фарма Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2012/000089 external-priority patent/WO2012095303A1/en
Application filed by Ноксон Фарма Аг filed Critical Ноксон Фарма Аг
Publication of RU2014132706A publication Critical patent/RU2014132706A/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/16Aptamers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/34Spatial arrangement of the modifications
    • C12N2310/344Position-specific modifications, e.g. on every purine, at the 3'-end
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/35Nature of the modification
    • C12N2310/351Conjugate
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00Applications; Uses
    • C12N2320/10Applications; Uses in screening processes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00Applications; Uses
    • C12N2320/30Special therapeutic applications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Pain & Pain Management (AREA)
  • Plant Pathology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2014132706A 2012-01-10 2013-01-10 Нуклеиновые кислоты, специфически связывающие cgrp RU2014132706A (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EPPCT/EP2012/000089 2012-01-10
PCT/EP2012/000089 WO2012095303A1 (en) 2011-01-10 2012-01-10 Nucleic acid molecule having binding affinity to a target molecule and a method for generating the same
EP12000105 2012-01-10
EP12000105.2 2012-01-10
PCT/EP2013/000055 WO2013104539A1 (en) 2012-01-10 2013-01-10 Nucleic acids specifically binding cgrp

Publications (1)

Publication Number Publication Date
RU2014132706A true RU2014132706A (ru) 2016-02-27

Family

ID=48781062

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2014132706A RU2014132706A (ru) 2012-01-10 2013-01-10 Нуклеиновые кислоты, специфически связывающие cgrp

Country Status (14)

Country Link
US (1) US9163243B2 (enExample)
EP (1) EP2802659A1 (enExample)
JP (1) JP2015506174A (enExample)
KR (1) KR20140111704A (enExample)
CN (1) CN104136612A (enExample)
AU (1) AU2013209130A1 (enExample)
BR (1) BR112014016939A2 (enExample)
CA (1) CA2860809A1 (enExample)
HK (1) HK1198370A1 (enExample)
IL (1) IL233515A0 (enExample)
MX (1) MX2014008456A (enExample)
RU (1) RU2014132706A (enExample)
SG (1) SG11201403769YA (enExample)
WO (1) WO2013104539A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2815444C2 (ru) * 2018-11-12 2024-03-15 Аптарион Биотех Аг Cxcl8-связывающие нуклеиновые кислоты

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014016877B1 (pt) 2012-01-10 2022-03-15 Aptarion Biotech Ag Molécula de l-ácido nucleico capaz de se ligar a c5a humana, seus usos, bem como composição farmacêutica, complexo, método para a seleção de um antagonista de uma atividade mediada por c5a e kit para a detecção de c5a
AU2015230933B2 (en) 2014-03-21 2020-08-13 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
JP6584868B2 (ja) * 2015-02-25 2019-10-02 学校法人 関西大学 ゲル素材及びその製造方法
US20170088612A1 (en) * 2015-09-24 2017-03-30 Teva Pharmaceuticals International Gmbh Preventing, treating, and reducing (persistent) post-traumatic headache
ES2607639B1 (es) 2015-09-30 2018-02-28 Urquima, S.A Sal de ácido maleico de un intermedio de silodosina
KR20220031944A (ko) 2016-09-23 2022-03-14 테바 파마슈티컬스 인터내셔널 게엠베하 불응성 편두통의 치료
WO2020098968A1 (en) 2018-11-12 2020-05-22 Aptarion Biotech Ag Cxcl8 binding nucleic acids

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6011020A (en) 1990-06-11 2000-01-04 Nexstar Pharmaceuticals, Inc. Nucleic acid ligand complexes
US5840867A (en) 1991-02-21 1998-11-24 Gilead Sciences, Inc. Aptamer analogs specific for biomolecules
US5582981A (en) 1991-08-14 1996-12-10 Gilead Sciences, Inc. Method for identifying an oligonucleotide aptamer specific for a target
US6682886B1 (en) 1994-04-28 2004-01-27 Gilead Sciences, Inc. Bivalent binding molecules of 7 transmembrane G protein-coupled receptors
JPH10504457A (ja) 1994-08-16 1998-05-06 ヒューマン ジノーム サイエンシーズ, インコーポレイテッド カルシトニンレセプター
WO1996038579A1 (en) 1995-06-02 1996-12-05 Nexstar Pharmaceuticals, Inc. High-affinity oligonucleotide ligands to growth factors
US6395029B1 (en) 1999-01-19 2002-05-28 The Children's Hospital Of Philadelphia Sustained delivery of polyionic bioactive agents
US6652886B2 (en) 2001-02-16 2003-11-25 Expression Genetics Biodegradable cationic copolymers of poly (alkylenimine) and poly (ethylene glycol) for the delivery of bioactive agents
RU2180311C1 (ru) 2001-07-05 2002-03-10 Мешалкин Георгий Алексеевич Защитная пробка
ES2346640T4 (es) 2001-10-26 2011-04-26 Noxxon Pharma Ag Ácido l-nucleico modificado.
EP1306382A1 (de) 2001-10-26 2003-05-02 Noxxon Pharma AG Modifizierte L-Nukleinsäure
EP2138575B8 (en) 2002-02-20 2013-07-24 Mersana Therapeutics, Inc. Conjugates comprising a biodegradable polymer and uses therefor
US7879991B2 (en) 2002-05-06 2011-02-01 Noxxon Pharma Ag CGRP binding nucleic acids
KR20060015505A (ko) 2003-04-13 2006-02-17 엔존 파마슈티컬즈, 인코포레이티드 올리고뉴클레오타이드 전구약물
GB0314472D0 (en) 2003-06-20 2003-07-23 Warwick Effect Polymers Ltd Polymer
US20090281296A1 (en) 2004-02-09 2009-11-12 Supramol Parenteral Colloid Gmbh Process for the production of conjugates from polysaccharides and polynucelotides
ES2741524T3 (es) 2004-03-23 2020-02-11 Ascendis Pharma Gmbh Profármaco polimérico con un enlazador autoinmolador
WO2006052790A2 (en) 2004-11-05 2006-05-18 The Children's Hospital Of Philadelphia Biodegradable linkers for molecular therapies
CA2607185A1 (en) * 2005-05-04 2006-11-09 Noxxon Pharma Ag Intracellular active agents
CN101534643A (zh) 2006-09-15 2009-09-16 安佐制药股份有限公司 用于递送寡核苷酸的基于位阻酯的生物可降解连接体
EP2407558A1 (en) 2006-10-31 2012-01-18 Noxxon Pharma AG Methods for the detection of a single- or double-stranded nucleic acid molecule
WO2011131371A1 (en) 2010-04-21 2011-10-27 Noxxon Pharma Ag Lipid binding nucleic acids
KR20140026357A (ko) * 2011-01-10 2014-03-05 녹손 파르마 아게 목표 분자에 결합력을 갖는 핵산 및 이를 제조하는 방법

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2815444C2 (ru) * 2018-11-12 2024-03-15 Аптарион Биотех Аг Cxcl8-связывающие нуклеиновые кислоты

Also Published As

Publication number Publication date
SG11201403769YA (en) 2014-07-30
KR20140111704A (ko) 2014-09-19
CN104136612A (zh) 2014-11-05
US20150031755A1 (en) 2015-01-29
HK1198370A1 (en) 2015-04-10
CA2860809A1 (en) 2013-07-18
JP2015506174A (ja) 2015-03-02
MX2014008456A (es) 2014-11-25
BR112014016939A2 (pt) 2019-09-24
AU2013209130A1 (en) 2014-07-10
IL233515A0 (en) 2014-08-31
WO2013104539A1 (en) 2013-07-18
EP2802659A1 (en) 2014-11-19
US9163243B2 (en) 2015-10-20

Similar Documents

Publication Publication Date Title
RU2014132706A (ru) Нуклеиновые кислоты, специфически связывающие cgrp
RU2014132708A (ru) НОВЫЕ СВЯЗЫВАЮЩИЕ C5a НУКЛЕИНОВЫЕ КИСЛОТЫ
DE69637430T2 (de) Neue opioid peptide, selektiv für kappa rezeptor
JP2015506174A5 (enExample)
JP2013524792A5 (enExample)
Suat et al. Design of β-turn based therapeutic agents
JP2015509705A5 (enExample)
EP2560689B1 (en) Novel self-assembling peptides and their use in the formation of hydrogels
DE69212914T2 (de) Schnellsynthese und Screening von Peptidmimetika
JP2014533098A5 (enExample)
RU2010116245A (ru) НУКЛЕИНОВЫЕ КИСЛОТЫ, СВЯЗЫВАЮЩИЕ C5a
CN1826353A (zh) 新的黑皮质素受体模板、肽及其用途
JP2010202653A (ja) 抗梗塞分子
Todorov et al. Synthesis, characterization and nociceptive screening of new VV-hemorphin-5 analogues
Sluka et al. Reagents and methods for the solid-phase synthesis of protein-EDTA for use in affinity cleaving
Kokko et al. In vitro analysis of stable, receptor-selective neurotensin [8− 13] analogues
Harris et al. Antinociceptive activity of thiazole-containing cyclized DAMGO and Leu-(Met) enkephalin analogs
Ogawa et al. Synthesis and Structure− Activity Relationships of an Orally Available and Long-Acting Analgesic Peptide, N α-Amidino-Tyr-d-Arg-Phe-MeβAla-OH (ADAMB)
US7144986B2 (en) Polypeptides comprising IL-6 ligand binding receptor domains
CN104877005A (zh) 非天然氨基酸修饰的内吗啡肽-1类似物及其合成和应用
EP2328925A1 (en) Peptides and peptidomimetic compounds, the manufacturing thereof as well as their use for preparing a therapeutically and/or preventively active pharmaceutical composition
CN101792487A (zh) 一种固相环化合成Laterocidin化合物的方法
US20080194467A1 (en) Cancer treatment methods using cadherin antagonists in combination with anticancer agents
DE4427980A1 (de) Nukleinsäuren-bindende Oligomere für Therapie und Diagnostik
CN107987126B (zh) 4位苯丙酰胺羟基化修饰的内吗啡肽类似物及其合成方法和应用

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20170403